Current treatment landscape for relapsed and/or refractory multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Multiple myeloma treatment has improved survival, but relapse remains a challenge.
• Relapsed myeloma is often more aggressive and treatment-refractory.
• Current treatment options for relapsed/refractory multiple myeloma include novel agents but lack a standard approach.

Purpose of the Study:

• To review the current treatment landscape for relapsed and/or refractory multiple myeloma.
• To highlight key disease-related and patient-related factors influencing treatment selection.

Main Methods:

• Review of recent phase II and III clinical trials.
• Analysis of efficacy data for approved agents in relapsed/refractory settings.
• Discussion of clinical considerations for treatment choice.

Main Results:

• Several immunomodulatory agents (lenalidomide, pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib) show efficacy.
• No universally accepted standard treatment exists for relapsed/refractory multiple myeloma.
• Disease characteristics and patient comorbidities impact treatment decisions.

Conclusions:

• Effective management of relapsed/refractory multiple myeloma requires careful consideration of available therapies.
• Individualized treatment strategies are crucial, balancing efficacy with patient-specific factors like comorbidities and toxicities.